-
-
-
-
-
-
-
Vir Biotechnology announces collaboration with Astellas for VIR-5500
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 33c, provides guidance
-
-
-
-
-
-
-
Vir Biotechnology enrolls first patient in ECLIPSE 2 hepatitis delta trial
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Vir Biotechnology (VIR)
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Vir Biotechnology (VIR)
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
-
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

